Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
New chief medical officer at SpringWorks Therapeutics, while Biomea Fusion gets new chief financial officer.
Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.
Executives On The Move: New Chief Science Officer At Janux, While New Senior Vice President Joins Pfizer
New chief financial officers at Verrica and Medexus Pharmaceuticals.
Relief for Helixmith’s management as voting at recent shareholders' meeting failed to remove top executives, including the South Korean biotech’s founder and CEO, following recent setbacks. But the future of the board may now depend largely on the success of the ongoing clinical trials for lead assets and stock price recovery.
Chief brand officer joins Moderna, plus new chief medical officer at Monopar Therapeutics.
The biotech sector is awash with capital and the rise of the virtual roadshow is breaking down geographic barriers, giving European firms a better chance to impress US investors.
Executives On The Move: New Chief Financial Officer Joins BioNTech, While Moderna Picks Up New Chief Medical Officer
Merck Gets New Chief Strategy Officer, New Chief Operating And Production Officer At CureVac.
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.
Leadership moves are also reported at CureVac, while Esperion Therapeutics and Palatin Technologies get new chief medical officers.
After more than three decades being associated with Novo Nordisk, Lars Rebien Sørensen has signed up to be chairman of Ferring, telling Scrip that the privately owned Swiss group's philosophy chimes with his own.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.